Literature DB >> 4076237

Differences in tumour and normal tissue concentrations of iodine- and indium-labelled monoclonal antibody. I. The effect on image contrast in clinical studies.

A C Perkins, M V Pimm.   

Abstract

The poor imaging characteristics of 131I have resulted in the use of alternative radionuclides for radiolabelling monoclonal antibodies. Clinical imaging studies have shown that, in addition to the more suitable energy of emission of 111In over 131I for gamma camera detection, the 111In-labelled antibody appears to clear from the bloodstream at a faster rate than that of 131I-labelled antibody, resulting in greater tumour-to-background image contrast. However, measurements of the activity in blood samples from patients demonstrate that both 131I- and 111In-labelled antibodies clear from the circulation at similar rates. This discrepancy is probably due to the different biological fates of the two radionuclides and warrants further scientific study.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4076237     DOI: 10.1007/BF00252340

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  18 in total

1.  The preparation and characterisation of 111In-labelled 791T/36 monoclonal antibody for tumour immunoscintigraphy.

Authors:  A C Perkins; M V Pimm; M K Birch
Journal:  Eur J Nucl Med       Date:  1985

2.  In vivo localization of anti-osteogenic sarcoma 791T monoclonal antibody in osteogenic sarcoma xenografts.

Authors:  M V Pimm; M J Embleton; A C Perkins; M R Price; R A Robins; G R Robinson; R W Baldwin
Journal:  Int J Cancer       Date:  1982-07-15       Impact factor: 7.396

3.  Radioimmunodetection of human colorectal cancers by an anti-tumour monoclonal antibody.

Authors:  P A Farrands; A C Perkins; M V Pimm; M J Embleton; J D Hardy; R W Baldwin; J D Hardcastle
Journal:  Lancet       Date:  1982-08-21       Impact factor: 79.321

4.  Targeting of iodine-123-labelled tumour-associated monoclonal antibodies to ovarian, breast, and gastrointestinal tumours.

Authors:  A A Epenetos; K E Britton; S Mather; J Shepherd; M Granowska; J Taylor-Papadimitriou; C C Nimmon; H Durbin; L R Hawkins; J S Malpas; W F Bodmer
Journal:  Lancet       Date:  1982-11-06       Impact factor: 79.321

5.  Liposomally entrapped second antibody improves tumour imaging with radiolabelled (first) antitumour antibody.

Authors:  R H Begent; P A Keep; A J Green; F Searle; K D Bagshawe; R F Jewkes; B E Jones; G M Barratt; B E Ryman
Journal:  Lancet       Date:  1982-10-02       Impact factor: 79.321

6.  The localization of an anti-tumour monoclonal antibody (791T/36) in gastrointestinal tumours.

Authors:  N C Armitage; A C Perkins; M V Pimm; P A Farrands; R W Baldwin; J D Hardcastle
Journal:  Br J Surg       Date:  1984-06       Impact factor: 6.939

7.  Clinical implications for immunoscintigraphy in patients with ovarian malignancy: a preliminary study using monoclonal antibody 791T/36.

Authors:  E M Symonds; A C Perkins; M V Pimm; R W Baldwin; J G Hardy; D A Williams
Journal:  Br J Obstet Gynaecol       Date:  1985-03

8.  Location of metastatic breast carcinoma by a monoclonal antibody chelate labelled with indium-111.

Authors:  R M Rainsbury; R J Ott; J H Westwood; T S Kalirai; R C Coombes; V R McCready; A M Neville; J C Gazet
Journal:  Lancet       Date:  1983-10-22       Impact factor: 79.321

9.  Localisation of human osteosarcoma by antitumour monoclonal antibody.

Authors:  P A Farrands; A Perkins; L Sully; J S Hopkins; M V Pimm; R W Baldwin; J D Hardcastle
Journal:  J Bone Joint Surg Br       Date:  1983-11

10.  The use of monoclonal antibody 791T/36 in the immunoscintigraphy of primary and metastatic carcinoma of the breast.

Authors:  M R Williams; A C Perkins; F C Campbell; M V Pimm; J G Hardy; M L Wastie; R W Blamey; R W Baldwin
Journal:  Clin Oncol       Date:  1984-12
View more
  7 in total

1.  Metallic radionuclides in the development of diagnostic and therapeutic radiopharmaceuticals.

Authors:  Sibaprasad Bhattacharyya; Manish Dixit
Journal:  Dalton Trans       Date:  2011-05-03       Impact factor: 4.390

2.  A new approach to image subtraction in immunoscintigraphy: preliminary results.

Authors:  J C Liehn; P Hannequin; S Nasca; D Lebrun; A Cattan; J Valeyre
Journal:  Eur J Nucl Med       Date:  1987

3.  Tissue retention of indium-labelled antibodies.

Authors:  A C Perkins; M V Pimm
Journal:  Eur J Nucl Med       Date:  1995-09

4.  Differences in tumour and normal tissue concentrations of iodine- and indium-labelled monoclonal antibody. II. Biodistribution studies in mice with human tumour xenografts.

Authors:  M V Pimm; A C Perkins; R W Baldwin
Journal:  Eur J Nucl Med       Date:  1985

5.  A comparison of iodine and indium labelled anti CEA intact antibody, F(ab)2 and Fab fragments by imaging tumour xenografts.

Authors:  S M Andrew; A C Perkins; M V Pimm; R W Baldwin
Journal:  Eur J Nucl Med       Date:  1988

6.  A fluorescence quenching method for estimating chelating groups in chelate-conjugated macromolecules.

Authors:  W Ma; K J Hwang; V H Lee
Journal:  Pharm Res       Date:  1993-02       Impact factor: 4.200

7.  Localization of human sarcoma with radiolabeled monoclonal antibody--a follow-up report.

Authors:  J A Greager; T C Chao; J M Brown; D G Pavel; M J Blend; T K Das Gupta
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.